BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31554638)

  • 1. A Neuropilin-1 Antagonist Exerts Antitumor Immunity by Inhibiting the Suppressive Function of Intratumoral Regulatory T Cells.
    Jung K; Kim JA; Kim YJ; Lee HW; Kim CH; Haam S; Kim YS
    Cancer Immunol Res; 2020 Jan; 8(1):46-56. PubMed ID: 31554638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoglobulin Fc-fused, neuropilin-1-specific peptide shows efficient tumor tissue penetration and inhibits tumor growth via anti-angiogenesis.
    Kim YJ; Bae J; Shin TH; Kang SH; Jeong M; Han Y; Park JH; Kim SK; Kim YS
    J Control Release; 2015 Oct; 216():56-68. PubMed ID: 26260451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-γ Drives T
    Overacre-Delgoffe AE; Chikina M; Dadey RE; Yano H; Brunazzi EA; Shayan G; Horne W; Moskovitz JM; Kolls JK; Sander C; Shuai Y; Normolle DP; Kirkwood JM; Ferris RL; Delgoffe GM; Bruno TC; Workman CJ; Vignali DAA
    Cell; 2017 Jun; 169(6):1130-1141.e11. PubMed ID: 28552348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer.
    Chuckran CA; Cillo AR; Moskovitz J; Overacre-Delgoffe A; Somasundaram AS; Shan F; Magnon GC; Kunning SR; Abecassis I; Zureikat AH; Luketich J; Pennathur A; Sembrat J; Rojas M; Merrick DT; Taylor SE; Orr B; Modugno F; Buckanovich R; Schoen RE; Kim S; Duvvuri U; Zeh H; Edwards R; Kirkwood JM; Coffman L; Ferris RL; Bruno TC; Vignali DAA
    Sci Transl Med; 2021 Dec; 13(623):eabf8495. PubMed ID: 34878821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer Exacerbates Ischemic Brain Injury Via Nrp1 (Neuropilin 1)-Mediated Accumulation of Regulatory T Cells Within the Tumor.
    Wang L; Zhou Y; Yin J; Gan Y; Wang X; Wen D; Thomson AW; Hu X; Yang L; Stetler RA; Li P; Yu W
    Stroke; 2018 Nov; 49(11):2733-2742. PubMed ID: 30355201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic depletion of CCR8
    Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin Fc-Fused Peptide without C-Terminal Arg or Lys Residue Augments Neuropilin-1-Dependent Tumor Vascular Permeability.
    Baek DS; Kim JH; Kim YJ; Kim YS
    Mol Pharm; 2018 Feb; 15(2):394-402. PubMed ID: 29232521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
    Gao Y; You M; Fu J; Tian M; Zhong X; Du C; Hong Z; Zhu Z; Liu J; Markowitz GJ; Wang FS; Yang P
    J Hepatol; 2022 Jan; 76(1):148-159. PubMed ID: 34689996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NKG2D-Fc fusion protein promotes antitumor immunity through the depletion of immunosuppressive cells.
    Feng PH; Lam B; Tseng SH; Kung YJ; Farmer E; Cheng MA; Hung CF
    Cancer Immunol Immunother; 2020 Oct; 69(10):2147-2155. PubMed ID: 32468232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer.
    Hu P; Arias RS; Sadun RE; Nien YC; Zhang N; Sabzevari H; Lutsiak ME; Khawli LA; Epstein AL
    Clin Cancer Res; 2008 Jan; 14(2):579-88. PubMed ID: 18223234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.
    Villarreal DO; L'Huillier A; Armington S; Mottershead C; Filippova EV; Coder BD; Petit RG; Princiotta MF
    Cancer Res; 2018 Sep; 78(18):5340-5348. PubMed ID: 30026324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models.
    Campbell JR; McDonald BR; Mesko PB; Siemers NO; Singh PB; Selby M; Sproul TW; Korman AJ; Vlach LM; Houser J; Sambanthamoorthy S; Lu K; Hatcher SV; Lohre J; Jain R; Lan RY
    Cancer Res; 2021 Jun; 81(11):2983-2994. PubMed ID: 33757978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid Depletion of Intratumoral Regulatory T Cells Induces Synchronized CD8 T- and NK-cell Activation and IFNγ-Dependent Tumor Vessel Regression.
    Kurebayashi Y; Olkowski CP; Lane KC; Vasalatiy OV; Xu BC; Okada R; Furusawa A; Choyke PL; Kobayashi H; Sato N
    Cancer Res; 2021 Jun; 81(11):3092-3104. PubMed ID: 33574087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment.
    Budhu S; Schaer DA; Li Y; Toledo-Crow R; Panageas K; Yang X; Zhong H; Houghton AN; Silverstein SC; Merghoub T; Wolchok JD
    Sci Signal; 2017 Aug; 10(494):. PubMed ID: 28851824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4+Foxp3+T Regulatory Cells Promote Transplantation Tolerance by Modulating Effector CD4+ T Cells in a Neuropilin-1-Dependent Manner.
    Campos-Mora M; Contreras-Kallens P; Gálvez-Jirón F; Rojas M; Rojas C; Refisch A; Cerda O; Pino-Lagos K
    Front Immunol; 2019; 10():882. PubMed ID: 31068948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
    Cohen AD; Schaer DA; Liu C; Li Y; Hirschhorn-Cymmerman D; Kim SC; Diab A; Rizzuto G; Duan F; Perales MA; Merghoub T; Houghton AN; Wolchok JD
    PLoS One; 2010 May; 5(5):e10436. PubMed ID: 20454651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.
    Mahne AE; Mauze S; Joyce-Shaikh B; Xia J; Bowman EP; Beebe AM; Cua DJ; Jain R
    Cancer Res; 2017 Mar; 77(5):1108-1118. PubMed ID: 28122327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
    Ha D; Tanaka A; Kibayashi T; Tanemura A; Sugiyama D; Wing JB; Lim EL; Teng KWW; Adeegbe D; Newell EW; Katayama I; Nishikawa H; Sakaguchi S
    Proc Natl Acad Sci U S A; 2019 Jan; 116(2):609-618. PubMed ID: 30587582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropilin-1 Regulates the Secondary CD8 T Cell Response to Virus Infection.
    Hwang JY; Sun Y; Carroll CR; Usherwood EJ
    mSphere; 2019 May; 4(3):. PubMed ID: 31118303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8
    Liu C; Chikina M; Deshpande R; Menk AV; Wang T; Tabib T; Brunazzi EA; Vignali KM; Sun M; Stolz DB; Lafyatis RA; Chen W; Delgoffe GM; Workman CJ; Wendell SG; Vignali DAA
    Immunity; 2019 Aug; 51(2):381-397.e6. PubMed ID: 31350177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.